SCHEMBL5544301

SCHEMBL5544301

NC(=O)N1CCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4097865 0.93
SCHEMBL2382694 0.91 CA2 (0.40)
Urea SCHEMBL2682647 0.89 CA2 (0.39)
SCHEMBL829063 0.79
SCHEMBL27399684 0.79 CA2 (0.41)
Hydrochloric Acid SCHEMBL10986584 0.77
SCHEMBL27508934 0.77
SCHEMBL4068512 0.75
SCHEMBL16611544 0.75
SCHEMBL17507593 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1993012817-A1 THERAPEUTIC COMBINATIONS USEFUL IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE WARNER-LAMBERT COMPANY (US) 1993-07-08 WO claimed
WO-1993003717-A1 CHOLECYSTOKININ ANTAGONISTS USEFUL FOR TREATING DEPRESSION WARNER-LAMBERT COMPANY (US) 1993-03-04 WO claimed
US-5153191-A Administering lorglumide or loxiglumide or salts thereof WARNER-LAMBERT COMPANY (US) 1992-10-06 US claimed
US-20240217978-A1 COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2024-07-04 US disclosed
EP-4326724-A1 COMPOUND AS ADENOSINE A2A RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2024-02-28 EP disclosed
WO-2022224180-A1 COMPOUND AS ADENOSINE A2A RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2022-10-27 WO disclosed
US-8735398-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-27 US disclosed
EP-2684039-A2 PEPTIDE DEFORMYLASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2014-01-15 EP disclosed
US-20130085147-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-04 US disclosed
US-8362020-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
WO-2012122450-A2 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-09-13 WO disclosed
US-6492531-B1 THE INVENTION CONCERNS CHOLECYSTOKININ (CCK) ANTAGONISTS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS. ESPECIALLY USEFUL ARE CCK.SUB.B ANTAGONISTS SUCH AS CI-988. WARNER-LAMBERT COMPANY 2002-12-10 US disclosed
EP-0686698-B1 Biotechnological process for the production of cyclic S-alpha-aminocarboxylic acids and R-alpha-aminocarboxylic acid amides LONZA AG (CH) 2001-03-14 EP disclosed
US-5798311-A INSECTICIDES ROHM AND HAAS COMPANY (US) 1998-08-25 US disclosed
US-5766893-A ENZYME CULTURE LONZA AG (CH) 1998-06-16 US disclosed
US-5622846-A RACEMIC MIXTURES OR OPTICALLY ACTIVE ISOMERS; MICROORGANISM WHICH USE THESE COMPOUNDS LONZA AG (CH) 1997-04-22 US disclosed
EP-0686698-A2 Biotechnological process for the production of cyclic S-alpha-aminocarboxylic acids and R-alpha-aminocarboxylic acid amides LONZA AG (CH) 1995-12-13 EP disclosed
WO-1993003717-A1 CHOLECYSTOKININ ANTAGONISTS USEFUL FOR TREATING DEPRESSION WARNER-LAMBERT COMPANY (US) 1993-03-04 WO disclosed
US-5153191-A Administering lorglumide or loxiglumide or salts thereof WARNER-LAMBERT COMPANY (US) 1992-10-06 US disclosed
US-4211876-A PROSTAGLANDIN ANTAGONIST E. I. DU PONT DE NEMOURS AND COMPANY (US) 1980-07-08 US disclosed